Evidence Hub

Urinary Tobacco and Nicotine Exposure Biomarkers as Predictors of Transitions between Cigarette and e-Cigarette Use in the Exhale Longitudinal Cohort Study

Brouwer AF, Shafie-Khorassani F, Benowitz N, Shi N, Baker TB, Hayes-Birchler T, Piper ME

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2026

371 participants

Abstract

Introduction: Urinary tobacco and nicotine exposure biomarkers may be predictive of subsequent transitions in product use.

Methods: We used data from an observational study of 371 adults who smoked cigarettes daily, some of whom also used e-cigarettes, and who were followed every 2 months for up to 2 years (Wisconsin, United States, 2015-2019). Using a multistate transition model, we assessed continuous associations between transition propensities and urinary tobacco biomarker concentrations, namely 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) (NNAL) and NE-2 (cotinine + trans-3'-hydroxycotinine), the nicotine metabolite ratio (NMR; trans-3'-hydroxycotinine:cotinine), and NNAL:NE-2, measured every 4 months.

Results: The biomarkers were generally more predictive of transitions from dual use, but not from cigarette-only use, than self-reported product use was. Propensity to stop smoking cigarettes decreased with increasing concentrations of NNAL and NE-2, for both participants who smoked only cigarettes and those who used both cigarettes and e-cigarettes. For example, we estimated that, at 20 pg NNAL per mg creatinine, 30.2% (95% CI = 14.6%, 47.0%) of those who only smoke cigarettes and 26.6% (95% CI = 11.3%, 42.5%) who dual use would transition to non-current cigarette use and e-cigarette use in 1 year, while at the 200 pg/ng, we estimate these probabilities to be 3.2% (95% CI = 1.7%, 5.8%) and 3.9% (95% CI = 1.9%, 8.5%), respectively. The ratio NNAL:NE-2 was predictive of…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 371 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free